Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094744298> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W3094744298 endingPage "20" @default.
- W3094744298 startingPage "20" @default.
- W3094744298 abstract "Background:Emicizumab, a humanized bispecific antibody, has been approved for the prophylactic treatment of hemophilia A in patients with and without inhibitors. Both activated partial thromboplastin time (APTT) based FVIII:C and inhibitor assays, as well as select chromogenic FVIII:C assays have been reported to be affected in the presence of emicizumab. Aims:To assess the effect of emicizumab spiked at 0, 25, 50, and 100 ug/mL into congenital FVIII deficient plasma, containing FVIII inhibitor at 0, 1 and 5 BU, in seven commonly used APTT and chromogenic based FVIII:C assays. Samples were also tested in an APTT and chromogenic based FVIII Nijmegen inhibitor assay. Methods:Four IVD approved, APTT based FVIII:C assays and three chromogenic FVIII:C assays were evaluated (Table 1). In addition, FVIII inhibitor levels were measured by Nijmegen Bethesda assay using either APTT (Actin®FSL, Siemens Healthcare) or chromogenic based (FVIII Chromogenic Assay, Siemens Healthcare) FVIII:C assays. Results:Reagent and dose-dependent increases in FVIII:C were observed for all APTT reagents tested as well as for the BIOPHEN FVIII:C chromogenic assay. The presence of low or high titer inhibitors did not impact APTT based FVIII:C measured. Neither of the two chromogenic FVIII:C assays, using bovine based FX and FIXa (i.e. FVIII Chromogenic Assay and Coatest®SP4) demonstrated measurable FVIII levels at any of the emicizumab concentrations tested. FVIII Nijmegen Bethesda inhibitor results using APTT based FVIII:C, when tested in the presence of emicizumab, consistently produced false negative results (Table 1) whereas results determined using the FVIII Chromogenic Assay measured inhibitor titers at expected concentrations. Conclusion:Confirming previously published results, emicizumab interferes in the APTT based FVIII:C and Nijmegen Bethesda inhibitor assays. Even at low emicizumab concentrations, false negative inhibitor titers are measured in APTT based inhibitor assays. Using a bovine based chromogenic FVIII:C assay is imperative when measuring both FVIII:C and FVIII inhibitors in samples containing emicizumab. Disclosures Tiefenbacher: Laboratory Corporation of America Holdings:Current Employment, Current equity holder in private company;Novo Nordisk:Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;Shire:Honoraria;Octapharma:Honoraria;Siemens Healthcare:Membership on an entity's Board of Directors or advisory committees;BioMarin:Membership on an entity's Board of Directors or advisory committees." @default.
- W3094744298 created "2020-11-09" @default.
- W3094744298 creator A5003002141 @default.
- W3094744298 creator A5009223634 @default.
- W3094744298 creator A5010276379 @default.
- W3094744298 creator A5011308287 @default.
- W3094744298 creator A5014697682 @default.
- W3094744298 creator A5015925828 @default.
- W3094744298 creator A5039637546 @default.
- W3094744298 creator A5043606297 @default.
- W3094744298 creator A5044944195 @default.
- W3094744298 creator A5070903702 @default.
- W3094744298 creator A5073819128 @default.
- W3094744298 date "2020-11-05" @default.
- W3094744298 modified "2023-09-27" @default.
- W3094744298 title "Assay Interference By Emicizumab in Aptt and Chromogenic Based FVIII:C and Inhibitor Assays" @default.
- W3094744298 doi "https://doi.org/10.1182/blood-2020-142132" @default.
- W3094744298 hasPublicationYear "2020" @default.
- W3094744298 type Work @default.
- W3094744298 sameAs 3094744298 @default.
- W3094744298 citedByCount "1" @default.
- W3094744298 countsByYear W30947442982022 @default.
- W3094744298 crossrefType "journal-article" @default.
- W3094744298 hasAuthorship W3094744298A5003002141 @default.
- W3094744298 hasAuthorship W3094744298A5009223634 @default.
- W3094744298 hasAuthorship W3094744298A5010276379 @default.
- W3094744298 hasAuthorship W3094744298A5011308287 @default.
- W3094744298 hasAuthorship W3094744298A5014697682 @default.
- W3094744298 hasAuthorship W3094744298A5015925828 @default.
- W3094744298 hasAuthorship W3094744298A5039637546 @default.
- W3094744298 hasAuthorship W3094744298A5043606297 @default.
- W3094744298 hasAuthorship W3094744298A5044944195 @default.
- W3094744298 hasAuthorship W3094744298A5070903702 @default.
- W3094744298 hasAuthorship W3094744298A5073819128 @default.
- W3094744298 hasConcept C126322002 @default.
- W3094744298 hasConcept C128463046 @default.
- W3094744298 hasConcept C153911025 @default.
- W3094744298 hasConcept C159654299 @default.
- W3094744298 hasConcept C185592680 @default.
- W3094744298 hasConcept C203014093 @default.
- W3094744298 hasConcept C2778261982 @default.
- W3094744298 hasConcept C2778382381 @default.
- W3094744298 hasConcept C43617362 @default.
- W3094744298 hasConcept C71924100 @default.
- W3094744298 hasConcept C86803240 @default.
- W3094744298 hasConceptScore W3094744298C126322002 @default.
- W3094744298 hasConceptScore W3094744298C128463046 @default.
- W3094744298 hasConceptScore W3094744298C153911025 @default.
- W3094744298 hasConceptScore W3094744298C159654299 @default.
- W3094744298 hasConceptScore W3094744298C185592680 @default.
- W3094744298 hasConceptScore W3094744298C203014093 @default.
- W3094744298 hasConceptScore W3094744298C2778261982 @default.
- W3094744298 hasConceptScore W3094744298C2778382381 @default.
- W3094744298 hasConceptScore W3094744298C43617362 @default.
- W3094744298 hasConceptScore W3094744298C71924100 @default.
- W3094744298 hasConceptScore W3094744298C86803240 @default.
- W3094744298 hasIssue "Supplement 1" @default.
- W3094744298 hasLocation W30947442981 @default.
- W3094744298 hasOpenAccess W3094744298 @default.
- W3094744298 hasPrimaryLocation W30947442981 @default.
- W3094744298 hasRelatedWork W1997732962 @default.
- W3094744298 hasRelatedWork W2056953534 @default.
- W3094744298 hasRelatedWork W2066004001 @default.
- W3094744298 hasRelatedWork W2419057739 @default.
- W3094744298 hasRelatedWork W2442247244 @default.
- W3094744298 hasRelatedWork W2944389084 @default.
- W3094744298 hasRelatedWork W3010744580 @default.
- W3094744298 hasRelatedWork W3093765735 @default.
- W3094744298 hasRelatedWork W3097101887 @default.
- W3094744298 hasRelatedWork W2884129166 @default.
- W3094744298 hasVolume "136" @default.
- W3094744298 isParatext "false" @default.
- W3094744298 isRetracted "false" @default.
- W3094744298 magId "3094744298" @default.
- W3094744298 workType "article" @default.